Drug Trial Radar · NCT02646566
Study of APD421 as PONV Treatment (Prior Prophylaxis)
Last checked: Nov 20, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
705
Actual
Start
Mar 2016
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- Acacia Pharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.
Conditions
- Postoperative Nausea and Vomiting
Interventions
APD421Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Complete Response (Success of Initial PONV Treatment)Time frame: 0-24 hours after administration of study medication
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Jackson Memorial Hospital
Miami, Florida
Duke University Medical Center
Durham, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina
Ohio State University
Columbus, Ohio
CHU de Hautepierre
Strasbourg, France
HELIOS Klinikum Aue
Aue, Germany
Universität Heidelberg
Heidelberg, Germany
Philipps University
Marburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.